SEC Form 4
ImmunityBio, Inc. (IBRX) insider trading
In the 12 months to Oct 26, 2026, 3 IBRX insiders reported open-market sales of $9.5M across 12 filings; no open-market purchases were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $9.5M
- 12 filings · 3 insiders
- Open-market purchases
- $0
- 0 filings
- Pre-arranged sales (10b5-1)
- 12 of 12
- All $9.5M sold was pre-arranged
Who traded IBRX, and when
- Sale
- Sale, pre-arranged (10b5-1)
IBRX daily close from Oct 27, 2025 to Oct 26, 2026, between $1.98 and $11.55, last $7.78. 12 sale and 0 purchase filings by 3 insiders, marked at their filing dates. Barry J. Simon, Director: sold $4.4M across 6 filings, first filed Jan 21, 2026, last Oct 6, 2026. Christobel Selecky, Director: sold $3.0M across 4 filings, first filed Jan 21, 2026, last Jul 6, 2026. Cheryl Cohen, Director: sold $2.1M across 2 filings, first filed Jul 6, 2026, last Oct 6, 2026.
Largest mark · tap a row for others
Barry J. Simon · Director
Filing 1 of 2 within a week · $2,684,389 total
Sale $1,783,602
175,000 shares at $10.19 avg
Filed Feb 24, 2026 · traded Feb 20
Pre-arranged (10b5-1) · close on filing date $11.55
Barry J. Simon · Director
Director
$4.4M soldChristobel Selecky · Director
Director
$3.0M soldCheryl Cohen · Director
Director
$2.1M soldOpen-market trades
12 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Barry J. Simon | Director | $4.4M | — | 6 | 100% of sales | |
| Christobel Selecky | Director | $3.0M | — | 4 | 100% of sales | |
| Cheryl Cohen | Director | $2.1M | — | 2 | 100% of sales |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Cheryl Cohen Director | SalePre-arranged (10b5-1) | 81,056 | $10.50 | $851.1K | 100,309 | |
traded | Barry J. Simon Director | SalePre-arranged (10b5-1) | 25,000 | $10.75 | $268.8K | 2,777,788 | |
traded | Cheryl Cohen Director | SalePre-arranged (10b5-1) | 131,210 | $9.50 | $1.2M | 125,386 | |
traded | Christobel Selecky Director | SalePre-arranged (10b5-1) | 159,478 | $9.02 | $1.4M | 0 | |
traded | Christobel Selecky Director | SalePre-arranged (10b5-1) | 96,722 | $9.01 | $871.2K | 0 | |
traded | Barry J. Simon Director | SalePre-arranged (10b5-1) | 25,000 | $7.88 | $196.9K | 2,802,788 | |
traded | Barry J. Simon Director | SalePre-arranged (10b5-1) | 23,033 | $7.18 | $165.3K | 2,827,788 | |
traded | Barry J. Simon Director | SalePre-arranged (10b5-1) | 75,000 | $12.01 | $900.8K | 2,850,821 | |
traded | Barry J. Simon Director | SalePre-arranged (10b5-1) | 175,000 | $10.19 | $1.8M | 2,925,821 | |
traded | Christobel Selecky Director | SalePre-arranged (10b5-1) | 25,000 | $10.00 | $250.0K | 0 | |
traded | Barry J. Simon Director | SalePre-arranged (10b5-1) | 151,967 | $7.20 | $1.1M | 3,166,604 | |
traded | Christobel Selecky Director | SalePre-arranged (10b5-1) | 75,000 | $5.84 | $437.7K | 0 |
GET /stocks/filings/vX/form-4?tickers=IBRX&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"IBRX"
],
"issuer_cik": "0001326110",
"owner_cik": "0001647994",
"accession_number": "0001326110-26-000085",
"form_type": "4",
"filing_date": "2026-10-06",
"period_of_report": "2026-10-05",
"issuer_name": "ImmunityBio, Inc.",
"issuer_trading_symbol": "IBRX",
"owner_name": "Simon Barry J.",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-10-05",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 25000,
"transaction_price_per_share": 10.7504,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 2777788,
"transaction_value": 268760,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 18, 2025."
},
{
"id": "F2",
"description": "Represents the weighted average share price of an aggregate total of 25,000 shares sold in the price range of $10.665 to $10.78 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, ImmunityBio, Inc. (the \"Issuer\") or a security holder of the Issuer, full information regarding the number of shares sold at each separate price."
}
]
},
{
"tickers": [
"IBRX"
],
"issuer_cik": "0001326110",
"owner_cik": "0001529371",
"accession_number": "0001326110-26-000084",
"form_type": "4",
"filing_date": "2026-10-06",
"period_of_report": "2026-10-02",
"issuer_name": "ImmunityBio, Inc.",
"issuer_trading_symbol": "IBRX",
"owner_name": "Cohen Cheryl",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-10-02",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 81056,
"transaction_price_per_share": 10.5,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 100309,
"transaction_value": 851088,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on February 27, 2026."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 35 records
- Option exercises23 records
- Tax withholding11 records
- Other1 record
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has ImmunityBio, Inc.'s CEO sold stock?
No. Richard Adcock (CEO) made no open-market sales filed as CEO in the last 12 months.
How current is IBRX’s insider data?
These are IBRX Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track IBRX insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for IBRX every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.